Skip to main content

Sionna Therapeutics (SION) Q2 2026 earnings — TrendMatrix coverage

MISS · WIDER LOSS-2.4% vs estimateEPS -$0.66 vs -$0.64 est

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
-$0.66
Estimate
-$0.64
Surprise
-2.4%

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q2 2026

How the report landed

Sionna Therapeutics (SION) reported a wider loss than forecast — diluted EPS of -$0.66 against the -$0.64 estimate (a 2.4% shortfall).

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks SION Earnings Q2 2026 earnings